What is Proton Therapy
Read our Covid-19 policy

Call Now For More Information

General Questions or
Schedule an Appointment


Current Patients


Physician Line


Read our Covid-19 policy

Advancements in Proton Therapy Treatment

Advancements in Proton Therapy Treatment

SCCA Proton Therapy is revolutionizing the way proton therapy is used in cancer treatment and has recently made investments in innovative technologies that will empower care teams to treat tumors more precisely. Building on the proton therapy delivery method of using a targeted dose of radiation to kill cancer cells while sparing surrounding normal tissues, the Center will now offer Pencil Beam Scanning (PBS) in its state-of-the-art gantry room.

“PBS is the most advanced way to deliver proton radiation and will allow us to sculpt protons for treating more complex tumors, such as in the head and neck, lung, abdomen, and pelvic areas,” said Smith ‘Jim’ Apisarnthanarax, MD, a radiation oncologist at SCCA Proton Therapy. 

Additionally, the Center is also the first proton facility to use an advanced breath hold device that helps patients in their ability to control breathing during radiation treatment. The Active Breathing Coordinator (ABC™) is most helpful in treating tumors in the chest or abdomen that move with breathing. The device supports patients by systematically holding their breath before or after they’ve breathed out. During this very short time, the tumor becomes a motionless target, allowing the treatment to be even more accurate, sparing surrounding tissue. The ABC™ device’s ability to control breath both on inhale and exhale allows physicians to treat a range of tumors.

“Providing patients with the best treatment possible is our number one priority and we believe investing in these advancements allows us to provide them with the highest levels of care,” said Ramesh Rengan, MD, medical director at SCCA Proton Therapy. “These innovative technologies will make treatments more effective for patients, while shortening the overall treatment course for select cancers.”